<DOC>
	<DOC>NCT00189735</DOC>
	<brief_summary>A dose finding study to evaluate the safety and effectiveness of FK778 in kidney transplant patients</brief_summary>
	<brief_title>A Study to Evaluate FK778 in Kidney Transplant Patients</brief_title>
	<detailed_description />
	<criteria>Patient has end stage kidney disease or needs retransplantation (loss of graft for nonimmunological reasons). Patient has been fully informed. Patient has an immunological high risk and/or having a previous graft survival shorter than 1 year due to immunological reasons. Patient has significant liver disease. Cold ischemia time of the donor kidney &gt;28 hours. Patient having uncontrolled concomitant infections and/or severe diarrhoea, vomiting, active upper gastrointestinal tract malabsorption or active peptic ulcer. Patient has previously received or is receiving an organ transplant other than kidney.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
	<keyword>Treatment Efficacy</keyword>
	<keyword>Treatment Effectiveness</keyword>
	<keyword>Anti-rejection therapy</keyword>
	<keyword>Immunosuppression</keyword>
	<keyword>Antirejection</keyword>
	<keyword>Malononitrilamide</keyword>
</DOC>